HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals?

S Martini; E David; F Tandoi; D Dell Olio; M Salizzoni; G M Saracco; R Romagnoli

doi:10.1111/ajt.14447

HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals?

Am J Transplant. 2017 Nov;17(11):2986-2987. doi: 10.1111/ajt.14447. Epub 2017 Aug 21.

Authors

S Martini¹, E David², F Tandoi³, D Dell Olio⁴, M Salizzoni³, G M Saracco¹, R Romagnoli³

Affiliations

¹ Gastrohepatology Unit, AOU Città della Salute e della Scienza di Torino, University of Torino, Turin, Italy.
² Pathology Unit, AOU Città della Salute e della Scienza di Torino, University of Torino, Turin, Italy.
³ Liver Transplantation Center and General Surgery 2U, AOU Città della Salute e della Scienza di Torino, University of Torino, Turin, Italy.
⁴ Regional Transplantation Center, Piedmont, AOU Città della Salute e della Scienza di Torino, University of Torino, Turin, Italy.

PMID: 28742943
DOI: 10.1111/ajt.14447

No abstract available

Keywords: cirrhosis; clinical research/practice; donors and donation:donor-derived infections; donors and donation:extended criteria; infection and infectious agents - viral: hepatitis C; liver transplantation/hepatology; organ acceptance; organ procurement and allocation.

Publication types

Letter
Comment

MeSH terms

Antiviral Agents*
Hepacivirus
Hepatitis C*
Humans
Tissue Donors
United States

Substances

Antiviral Agents